Acasti Pharma

ACST-X

Analysis and Opinions about ACST-X

Signal
Opinion
Expert
COMMENT
COMMENT
January 2, 2015

Acasti Pharma (APO-X) and Neptune Tech & Bioresource (NTB-T) comparison? The key for both companies is the use of krill to extract fish oil. The target would be for high lipids in blood. They can be taken alone or used in combination with statin drugs. The testing has been finished and it works. This stock is covered by only one analyst who is forecasting they are going to lose $0.06 in February year end, but will turn around and earn $0.22 in 2016. Speculative.

Show full opinionHide full opinion
Acasti Pharma (ACST-X)
January 2, 2015

Acasti Pharma (APO-X) and Neptune Tech & Bioresource (NTB-T) comparison? The key for both companies is the use of krill to extract fish oil. The target would be for high lipids in blood. They can be taken alone or used in combination with statin drugs. The testing has been finished and it works. This stock is covered by only one analyst who is forecasting they are going to lose $0.06 in February year end, but will turn around and earn $0.22 in 2016. Speculative.

COMMENT
COMMENT
December 10, 2014

Thinks there will be an event next year that will get the stock up above $1. Has been a poor performer this year. At the end of September, they came out with phase II trial results on their big Capri drug. Trial results were good. The current drug is a multimillion dollar drug that reduces triglyceride by 20%. This company’s drug, with half the dosage, came out with a 40% reduction. Because there were a bunch of short term players that when the stock didn’t pop a lot immediately, they decided to bail which has put on some selling pressure. For a company with a $30 million Enterprise Value, you are investing in something that would probably be in the half billion dollar range in the US. There is huge upside in the stock. New management is coming in, and once the phase 3 trial comes in, you are likely to see the stock really accelerate upwards.

Show full opinionHide full opinion
Acasti Pharma (ACST-X)
December 10, 2014

Thinks there will be an event next year that will get the stock up above $1. Has been a poor performer this year. At the end of September, they came out with phase II trial results on their big Capri drug. Trial results were good. The current drug is a multimillion dollar drug that reduces triglyceride by 20%. This company’s drug, with half the dosage, came out with a 40% reduction. Because there were a bunch of short term players that when the stock didn’t pop a lot immediately, they decided to bail which has put on some selling pressure. For a company with a $30 million Enterprise Value, you are investing in something that would probably be in the half billion dollar range in the US. There is huge upside in the stock. New management is coming in, and once the phase 3 trial comes in, you are likely to see the stock really accelerate upwards.

STRONG BUY
STRONG BUY
December 6, 2013

Developing a revolutionary cholesterol/glycerids treatment (CaPre). Had to finance to raise money for a phase 3 trial. A table pounding buy. Stock has been beaten up on short-term concerns. Looking for this to double or triple in the next year.

Show full opinionHide full opinion
Acasti Pharma (ACST-X)
December 6, 2013

Developing a revolutionary cholesterol/glycerids treatment (CaPre). Had to finance to raise money for a phase 3 trial. A table pounding buy. Stock has been beaten up on short-term concerns. Looking for this to double or triple in the next year.

STRONG BUY
STRONG BUY
September 4, 2013

(Market Call Minute.) Doing two phase 2 trials. Good results. (See Top Picks).

Show full opinionHide full opinion
Acasti Pharma (ACST-X)
September 4, 2013

(Market Call Minute.) Doing two phase 2 trials. Good results. (See Top Picks).

Showing 16 to 19 of 19 entries